Testosterone therapy for high-risk prostate cancer survivors:a systematic review and meta-analysis
| Autor: | Tet Yap, Fiona Teeling, Majed Shabbir, Kamran Ahmed, Prokar Dasgupta, Nicholas Raison |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Oncology
Biochemical recurrence Male medicine.medical_specialty Urology 030232 urology & nephrology MEDLINE Risk Assessment 03 medical and health sciences Prostate cancer 0302 clinical medicine Primary outcome Cancer Survivors Internal medicine medicine Humans Testosterone business.industry breakpoint cluster region Prostatic Neoplasms Testosterone (patch) medicine.disease Testosterone therapy 030220 oncology & carcinogenesis Meta-analysis business Risk assessment |
| Zdroj: | Teeling, F, Raison, M N, Shabbir, M M, Yap, M T, Dasgupta, P P & Ahmed, M K 2019, ' Testosterone therapy for high-risk prostate cancer survivors : a systematic review and meta-analysis ', Urology, vol. 126, pp. 16-23 . https://doi.org/10.1016/j.urology.2018.07.064 |
| DOI: | 10.1016/j.urology.2018.07.064 |
| Popis: | A systematic review and meta-analysis was performed to determine the relationship between testosterone therapy and risk of recurrence in testosterone-deficient survivors of curatively treated high-risk prostate cancer. Primary outcome was the risk of biochemical recurrence (BCR) in 109 high-risk patients in 13 included studies (1997-2017). Biochemical and symptomatic effects of therapy were also reviewed. The BCR rate was 0.00 (0.00-0.05), lower than the expected rate for high-risk prostate cancer survivors, suggesting that testosterone therapy may not increase their BCR risk. However, this is uncertain as the available evidence is of very low quality. Testosterone therapy remains investigational in this group. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|